Skip to main content
Year archive

Formycon AG — 2023 filings

All 29 regulatory filings released by Formycon AG (FYB) in 2023, sourced directly from the official regulator.

29 Filings
2023 Period
2023 filings (29)
Filing Released Lang
Formycon announces EMA acceptance of the MAA for FYB203, a biosimilar candidate to Eylea (Aflibercept)
Regulatory Filings
2023-12-27 English
Health Canada approves FYB201/Ranopto (Ranibizumab), a biosimilar to Lucentis
Regulatory Filings
2023-12-07 English
Formycon announces participation in international Investor Conferences in Q1/2024
Report Publication Announcement
2023-12-05 English
Formycon and Fresenius Kabi announce File Acceptance for FYB202, a biosimilar candidate to Stelara (ustekinumab), by the U.S. Food and Drug Administration
Regulatory Filings
2023-11-30 English
Formycon announces EMA submission for FYB203, a biosimilar candidate to Eylea (Aflibercept)
Regulatory Filings
2023-11-27 English
Formycon publishes nine-month results for 2023
Earnings Release 9M 2023
2023-11-13 English
Formycon hosts conference call on nine-month figures 2023 and presents at further investor conferences
Report Publication Announcement
2023-11-10 English
Formycon Ranibizumab Biosimilar FYB201/CIMERLI1 achieved 25% market share2 in the United States
Earnings Release Q3 2023
2023-10-10 English
Formycon and Fresenius Kabi announce European Medicines Agency Submission Acceptance of the Marketing Authorization Application for FYB202, an Ustekinumab Biosimilar Candidate
Regulatory Filings
2023-09-29 English
Formycon reports successful first half of 2023
Earnings Release H1 2023
2023-08-30 English
Half-yearly financial statements 2023
Interim / Quarterly Report H2 2023
2023-08-30 English
Formycon announces File Acceptance for FYB203, a biosimilar candidate to Eylea1 (aflibercept), by the U.S. Food and Drug Administration (FDA)
Legal Proceedings Report
2023-08-29 English
Formycon hosts conference call on financial and earnings position for H1 2023
Report Publication Announcement H1 2023
2023-08-23 English
Formycon and Fresenius Kabi secure U.S. License Date for proposed Ustekinumab Biosimilar
Regulatory Filings
2023-08-07 English
Formycon reports on the regular Annual General Meeting
AGM Information
2023-07-26 English
Formycon announces submission of the biologics license application (BLA) for FYB203, an aflibercept biosimilar candidate to the U.S. Food and Drug Administration (FDA)
Legal Proceedings Report
2023-06-29 English
Formycon reports results for the first quarter 2023
Earnings Release Q1 2023
2023-05-30 English
Formycon Announces Participation in International Investor Conferences in Q2/2023
Report Publication Announcement
2023-05-10 English
Annual financial statements 2022
Annual Report FY 2022
2023-05-05 German
Formycon publishes results for financial year 2022
Earnings Release FY 2022
2023-04-27 English
Formycon announces successful results of Phase I clinical trial for ustekinumab biosimilar candidate FYB202 and concludes clinical development
Regulatory Filings
2023-04-25 English
Jahresabschluss zum Geschäftsjahr vom 01.01.2021 bis zum 31.12.2021
Management Reports FY 2021
2023-03-06 German
Enno Spillner appointed Chief Financial Officer (CFO) of Formycon AG
Board/Management Information
2023-02-07 English
Aflibercept Biosimilar Candidate FYB203 shows comparable efficacy to the reference product Eylea1 in Phase III Study
Regulatory Filings
2023-02-06 English
Formycon and Fresenius Kabi conclude global commercialization partnership for FYB202, a biosimilar candidate to Stelara1 (ustekinumab)
Regulatory Filings
2023-02-02 English
Formycon AG announces result of private placement and sets placement price for the new shares from the capital increase
Share Issue/Capital Change
2023-02-02 English
Formycon AG upsizes capital increase from authorized capital following strong demand
Capital/Financing Update
2023-02-01 English
Formycon AG announces global license agreement with Fresenius Kabi for FYB202, a biosimilar candidate to Stelara1 (ustekinumab)
Major Shareholding Notification
2023-02-01 English
Formycon announces binding Term Sheet between Klinge Biopharma and Coherus BioSciences for the exclusive commercialization of FYB203, a biosimilar candidate to Eylea1, in the United States
M&A Activity
2023-01-09 English